Pfizer’s Paxlovid And The Murky World Of Rx Drug Communication
Executive Summary
Pfizer social media announcement that it’s seeking full approval for the oral COVID antiviral raise questions about where the line is on promotion versus other communications, FDA’s ability to regulate pharma on social media, and the unique considerations of promotion under EUAs.
You may also be interested in...
Biden’s ‘Test To Treat’ Plan Will Include Merck And Pfizer COVID Pills, But Only One Gets Public Thanks
Hundreds of pharmacy-based clinics and community health centers will offer free COVID testing and treatment. Government has secured 20 million doses of Pfizer’s Paxlovid, deemed to be a ‘game changer,’ though Merck’s molnupiravir is expected to be important in long-term care facilities.
FDA Creates Division To Support First Amendment Policy Development, Oversee Advertising Research
Multiple unfavorable court decisions have forced the agency to adjust its advertising enforcement strategies.
FDA’s Twitter Formula Allows Tweets About Products Without Excessive Risks
FDA’s draft guidance on presenting product information on social media platforms with character space limitations includes an equation for sending a tweet.